Two new hepatitis C combination drugs from Gilead and Merck Sharp and Dohme (MSD), that negate the need for interferon therapy and its hated side effects, have been recommended for approval
New faster-acting and more effective treatments for Hepatitis C are transforming treatment - offering a cure for, and even eradication of, the potentially fatal infection.
